HIV Preexposure Prophylaxis: A Review

@article{Riddell2018HIVPP,
  title={HIV Preexposure Prophylaxis: A Review},
  author={J. Riddell and K. Amico and K. Mayer},
  journal={JAMA},
  year={2018},
  volume={319},
  pages={1261–1268}
}
Importance About 40 000 Americans and 2 million people worldwide are newly infected with HIV each year. The combination antiretroviral regimen, tenofovir disoproxil fumarate (TDF)/emtricitabine, taken as a single pill once daily, has been shown to prevent HIV transmission but is used by fewer than 20% of people who could benefit in the United States. Observations PubMed was searched on February 15, 2018, using the search terms pre-exposure, prophylaxis, HIV, and PrEP to identify English… Expand
Seroconversion on preexposure prophylaxis.
The success achieved in the last decade in HIV/AIDS treatment with combination antiretroviral therapy (cART) has not been paralleled by remarkable improvements in the effectiveness of HIV preventionExpand
Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020
TLDR
Data support the safety of PrEP for adolescents, and PrEP adherence declined over time in the studies evaluating PrEP among adolescents, a trend that also has been observed among adult patients. Expand
PrEParing for Preexposure Prophylaxis
TLDR
This article aims to increase provider awareness of PrEP so primary care providers feel confident discussing risk reduction options, initiating, and monitoring PrEP, and to increase the confidence of PCPs in prescribing PrEP to those who would benefit from it. Expand
Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis
The antiretroviral drugs, tenofovir and emtricitabine used as preexposure prophylaxis (PrEP), are also used in treatment of HIV. Drug resistance due to PrEP can therefore jeopardize future treatmentExpand
Taking the daily grind out of HIV prevention
TLDR
There is an urgent need to develop new user-friendly PrEP or PEP dosage forms and dosing regimens for high-risk populations and the biological efficacy of a triple combination of HIV inhibitors in a macaque HIV infection model is described. Expand
Updates on HIV nonoccupational postexposure prophylaxis.
TLDR
Research of HIV nPEP shows that it is effective when used correctly, but there needs to be increased education and awareness to increase provider prescription and patient use as well as institutional changes to help patients complete the full course of medication. Expand
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques
TLDR
It is shown that single-dose prophylaxis before or after sex is a promising HIV prevention strategy and carefully designed clinical trials are needed to determine if any of these strategies will be effective in humans. Expand
HIV Preexposure Prophylaxis Among Adolescents in the US: A Review.
TLDR
This review assesses the current status of PrEP uptake among at-risk adolescents aged 13 to 19 years and recommendations for improving PrEP access, uptake, and future needed directions, including specific recommendations for health care professionals. Expand
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults
TLDR
F/TAF is non-inferior to F/TDF at preventing HIV acquisition in men and transgender women with a trend toward superiority but has yet to be tested against HIV exposure via injection or vaginal intercourse. Expand
Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe
Pre-exposure prophylaxis (PrEP) is a significant public health intervention with proven efficacy and safety in the prevention of human immunodeficiency virus (HIV) infection, which has taken aExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Preexposure prophylaxis for HIV infection among African women.
TLDR
Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low. Expand
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
TLDR
None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low. Expand
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
TLDR
The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men, and the treatment was associated with increased rates of gastrointestinal and renal adverse events. Expand
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
TLDR
Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown. Expand
Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians.
TLDR
Despite 2 decades of highly active antiretroviral therapy (HAART), HIV infection rates globally remain high (about 2 million new infections annually), even though HIV transmission is substantially attenuated when individuals use antifiltration therapy. Expand
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
TLDR
Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects and Detectable blood levels strongly correlated with the prophylactic effect. Expand
Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men
TLDR
PrEP using oral FTC-TDF tablets is a robust intervention for preventing HIV acquisition among men who have sex with men, and specific drug concentrations associated with protection from HIV-1 acquisition in the iPrEx trial are estimated. Expand
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.
TLDR
Provided that these results apply to women in Southern Africa, future prevention trial designs in that region should account for potentially reduced HIV incidence when PrEP is available. Expand
The current status of the use of oral medication to prevent HIV transmission
TLDR
PrEP can be effective in decreasing HIV transmission to at-risk uninfected persons, but further research is needed to determine the optimal modes of delivery. Expand
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
TLDR
Across populations and PrEP regimens, PrEP significantly reduced the risk of HIV acquisition compared with placebo, and there is no evidence of behavioral risk compensation. Expand
...
1
2
3
4
5
...